
Negroski detailed a real-world analysis on cladribine, an FDA-approved DMT, in an aging population of MS, and the recent increase in research for older populations with the disease.
Negroski detailed a real-world analysis on cladribine, an FDA-approved DMT, in an aging population of MS, and the recent increase in research for older populations with the disease.
Over the 3-year treatment period, buntanetap resulted in improvements in motor and nonmotor functions in patients with postural instability and gait difficulty, a group with faster disease progression.
In this episode, Negroski gave insight on the impact of health care-related social determinants of health, their impact on brain structure and aging in MS, and where efforts should be directed towards going forward.
The neurologist at Baptist Health provided context on identifying treatment approaches for varying degrees of migraine, the need to optimize medication use, and when patients may be experiencing more than just migraine.
in both the overall population and a per-procotol population, PrimeC-treated individuals experienced improvements on ALS Functional Rating Scale and increased survival compared with placebo.
The approval of donanemab marks the third antiamyloid therapy to gain the FDA's greenlight, following the conditional approval of aducanumab in 2021, and lecanemab in 2023—although aducanumab no longer remains on market after it was removed earlier this year.
Recent results from the SELECT-HD trial showed that WVE-003 was generally safe and had a well-tolerated profile in a 30 mg multidose cohort of patients with Huntington disease.
Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.
Following the 12-week program, participants reported numerous physical and neuropsychiatric benefits in their daily living, such as increased energy level, better mood, and improvement in balance.
The newly added cohort allows for greater opportunity to treat patients earlier, with the hope of impacting disease course and preserving muscle.
The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]
Suvecaltamide did not meet the primary endpoint in the phase 2b trial but showed numeric improvements and was well-tolerated.
Here's some of what is coming soon to NeurologyLive® this week.
Vitrisiran demonstrated a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events in both the overall population and those who received a monotherapy of vutrisiran without tafamidis.
The professor and chair of neurology at New York Medical College discussed her extensive involvement in neurology education and the recent efforts to enhance neurology education through various programs. [WATCH TIME: 5 minutes]
Neurology News Network. for the week ending June 29, 2024. [WATCH TIME: 3 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy/Dravet syndrome.
The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed how combining advanced therapies with lifestyle modifications can improve outcomes and slow disease progression in patients with multiple sclerosis. [WATCH TIME: 4 minutes]
After following patients for more than 10 years, arrhythmias were considered the most important cardiac predictor of survival, with progressive neurologic disability and diabetes mellitus identified as further major contributors.
Overall, the treatment resulted in dose-dependent trends of improvement on key clinical measures including Total Functional Capacity and Composite Unified Hungtinton's Disease Rating Scale.
The Cleveland Clinic Foundation Parkinson's Inpatient Program is a proactive, multidisciplinary intervention aimed to enhance the quality and safety of care for hospitalized patients with Parkinson disease.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 28, 2024.
The director of the OhioHealth ALS Clinic and vice chair of the ALS Association Care Services Committee discussed the upcoming ALS Nexus Conference and how themes of the event align with the direction of clinical care. [WATCH TIME: 3 minutes]
Anaya, a young woman with myasthenia gravis, discusses her challenges and triumphs living with a rare disease. She shares her personal story of advocacy and community, finding strength in the disease's impact on her independence and identity.
As part of our monthly clinician spotlight, NeurologyLive® highlighted seizure disorder expert Danielle Andrade, MD, MSc, FRCPC, director of the Adult Genetic Epilepsy Program at the University of Toronto.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne Marie Morse, DO, FAAN. [LISTEN TIME: 18 minutes]
In this segment, Negroski comments on the realism behind wearing off effect of treatments, specifically ocrelizumab, and how clinicians may work around some of these issues.
Additional data of a phase 2 study presented at the 2024 SLEEP Annual Meeting demonstrated that pitolisant significantly improved in secondary end points among patients with myotonic dystrophy type 1.
Negroski discussed some of the takeaways from an analysis of patients with stable MS who chose to switch from natalizumab to other, more moderate-efficacy oral disease-modifying therapies.
Clinically meaningful reductions in seizures through fenfluramine is likely to contribute to nonseizure benefits such as improvement in comorbidities, decreased use of other antiseizure medications, and reduction in premature death.